SNORD1C: The RNA molecule that could be a drug target or biomarker

Target Name: SNORD1C

NCBI ID: G677850

SNORD1C

Other Name(s): Small nucleolar RNA, C/D box 1C | R38C | small nucleolar RNA, C/D box 1C | snR38C

SNORD1C: The RNA molecule that could be a drug target or biomarker

Small nucleolar RNA (snRNA), also known as C/D box RNA (CBP), is a class of non-coding RNA molecule that plays a critical role in the regulation of gene expression in various organisms, including humans. One of the well -known snRNAs is SNORD1C, which has been identified as a potential drug target or biomarker.

SNORD1C is a 24.1 kilobase (kb) long RNA molecule that contains 11 exons and 11 introns. It is located in the 5'-end of the gene GTK-1 (Gene Expression and Genome Initiation) on chromosome 16. SNORD1C is a good candidate for a drug target because it has a conserved binding site in its sequence, which can be targeted by small molecule inhibitors.

The discovery of SNORD1C as a potential drug target comes from a study by the research groups led by Dr. Qin Liu, a professor in the Department of Molecular and Cell Biology at Stanford University, and Dr. Zhiyun Liu, a postdoctoral researcher in the same laboratory. They discovered that SNORD1C was highly expressed in various tissues and cancer types, including lung, breast, and ovarian cancer.

Furthermore, they found that SNORD1C was positively correlated with the expression of the gene encoding the protocellin protein (PTEN), a known tumor suppressor gene that can be mutated or deleted in various diseases, including cancer. This suggests that SNORD1C may play a role in the regulation of PTEN expression and could be a potential biomarker for cancer.

In addition to its potential as a drug target or biomarker, SNORD1C also has important functions in the regulation of gene expression. It is involved in the translation of mRNAs to the ribosome, where they are translated into proteins. Therefore, changes in the expression level of SNORD1C may affect the levels of protein produced from mRNAs, which could have implications for the regulation of various cellular processes.

The study also suggested that SNORD1C may be a potential target for small molecule inhibitors that can be used to treat cancer. The researchers used a variety of techniques, including RNA interference, RNA aptamer binding experiments, and mass spectrometry, to demonstrate that SNORD1C can be targeted by small molecule inhibitors. These results suggest that SNORD1C may be an attractive drug target or biomarker for the development of cancer therapies.

In conclusion, SNORD1C is a well-known snRNA molecule that has been identified as a potential drug target or biomarker for cancer. Its conserved binding site and positive correlation with the expression of the tumor suppressor gene PTEN make it an attractive target for small molecule inhibitors . Further studies are needed to confirm its potential as a drug target or biomarker, as well as its functions in the regulation of gene expression.

Protein Name: Small Nucleolar RNA, C/D Box 1C

The "SNORD1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets